Frunevetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Rat |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Solensia |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Frunevetmab, sold under the brand name Solensia, is a monoclonal antibody used to treat pain associated with osteoarthritis in cats.[3]
It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species.[3]
Frunevetmab is the international nonproprietary name (INN).[5]
Clinical usage
Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.[3] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.[3]
Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[3][4]
The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).[3]
History
In February 2021, Frunevetmab was approved for medical use in the European Union.[4]
In January 2022, the following year, Frunevetmab was approved for medical use in the United States.[3][6]
Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. [7]
References
- ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
- ^ "NADA 141-546 Solensia™ frunevetmab injection Injectable Solution Cats". animaldrugsatfda.fda.gov. Archived from the original on 15 January 2022. [bare URL PDF]
- ^ a b c d e f g h "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022.
This article incorporates text from this source, which is in the public domain.
- ^ a b c "Solensia EPAR". European Medicines Agency (EMA). 11 December 2020. Archived from the original on 15 January 2022. Retrieved 14 January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
- ^ "Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats". Zoetis. 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022.
- ^ "FDA Approves Pain Reliever for Cats Considered Too Risky for Humans". 14 January 2022.
This article incorporates public domain material from the United States Department of Health and Human Services
Bibliography
- Gruen ME, Myers JA, Lascelles BD (2021). "Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study". Frontiers in Veterinary Science. 8: 610028. doi:10.3389/fvets.2021.610028. PMC 8195238. PMID 34124212.
 | This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it. |